aluates Reports

$ 0.0

Automative

Global PD-L1 Biomarker Testing Market Research Report 2026

Published Date: 2026-02-25

Report Code: QYRE-Auto-6F9402

Global PD L1 Biomarker Testing Market Size Status and Forecast 2022

BUY CHAPTERS

Global PD-L1 Biomarker Testing Market Research Report 2026

Code: QYRE-Auto-6F9402

Report

2026-02-25

Pages:104

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Agilent Technologies

Roche

Merck

Bristol–Myers Squibb

Astrazeneca plc

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

PD-L1 Biomarker Testing Market Size

The global PD-L1 Biomarker Testing market was valued at US$ 3796 million in 2025 and is anticipated to reach US$ 36440 million by 2032, at a CAGR of 38.7% from 2026 to 2032.

PD-L1 Biomarker Testing Market

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances. Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart). PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies. PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

The PD‑L1 biomarker testing market is being propelled by the rapid expansion of immune checkpoint inhibitor therapies, particularly those targeting the PD‑1/PD‑L1 axis, which have shown remarkable clinical success in treating various advanced cancers—spurring widespread demand for stratifying patients based on PD‑L1 expression to optimize treatment outcomes. Additionally, the shift toward precision medicine has heightened the importance of molecular diagnostics. Clinicians and pharmaceutical developers are increasingly emphasizing personalized approaches, using PD‑L1 testing to guide therapeutic decisions and enable companion diagnostics—especially as diagnostic technologies advance to include automated IHC systems, NGS platforms, and AI-enhanced analysis .

Despite these positive trends, the PD‑L1 testing landscape faces significant obstacles due to a lack of standardization across protocols, assay clones, scoring systems, and cut-off thresholds. This inconsistency manifests in discordant results (with variability rates reported between 19–32% across different assays), undermining diagnostic reliability and complicating clinical decision-making. Moreover, high costs associated with advanced testing techniques (IHC, NGS) and uneven reimbursement frameworks create economic barriers, particularly in developing regions, impeding broad accessibility and exacerbating healthcare disparities.

The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2024 is about 21.68%. PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2024 is about 52.7%.

This report delivers a comprehensive overview of the global PD-L1 Biomarker Testing market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding PD-L1 Biomarker Testing. The PD-L1 Biomarker Testing market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global PD-L1 Biomarker Testing market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist PD-L1 Biomarker Testing manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of PD-L1 Biomarker Testing Market Report

Report Metric	Details
Report Name	PD-L1 Biomarker Testing Market
Accounted market size in 2025	US$ 3796 million
Forecasted market size in 2032	US$ 36440 million
CAGR	38.7%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	PD-L1 (22C3) PD-L1(28-8) PD-L1 (SP142) PD-L1 (SP263) Other
Segment by Application	Hospital Diagnostic Center Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for PD-L1 Biomarker Testing companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is PD-L1 Biomarker Testing Market growing?

Ans: The PD-L1 Biomarker Testing Market witnessing a CAGR of 38.7% during the forecast period 2026-2032.

What is the PD-L1 Biomarker Testing Market size in 2032?

Ans: The PD-L1 Biomarker Testing Market size in 2032 will be US$ 36440 million.

What is the PD-L1 Biomarker Testing Market share by application?

Ans: The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2024 is about 52.7%.

Who are the main players in the PD-L1 Biomarker Testing Market report?

Ans: The main players in the PD-L1 Biomarker Testing Market are Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences

What are the Application segmentation covered in the PD-L1 Biomarker Testing Market report?

Ans: The Applications covered in the PD-L1 Biomarker Testing Market report are Hospital, Diagnostic Center, Others

What are the Type segmentation covered in the PD-L1 Biomarker Testing Market report?

Ans: The Types covered in the PD-L1 Biomarker Testing Market report are PD-L1 (22C3), PD-L1(28-8), PD-L1 (SP142), PD-L1 (SP263), Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global PD-L1 Biomarker Testing Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 PD-L1 (22C3)

1.2.3 PD-L1(28-8)

1.2.4 PD-L1 (SP142)

1.2.5 PD-L1 (SP263)

1.2.6 Other

1.3 Market by Application

1.3.1 Global PD-L1 Biomarker Testing Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Hospital

1.3.3 Diagnostic Center

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global PD-L1 Biomarker Testing Market Perspective (2021–2032)

2.2 Global PD-L1 Biomarker Testing Growth Trends by Region

2.2.1 Global PD-L1 Biomarker Testing Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 PD-L1 Biomarker Testing Historic Market Size by Region (2021–2026)

2.2.3 PD-L1 Biomarker Testing Forecasted Market Size by Region (2027–2032)

2.3 PD-L1 Biomarker Testing Market Dynamics

2.3.1 PD-L1 Biomarker Testing Industry Trends

2.3.2 PD-L1 Biomarker Testing Market Drivers

2.3.3 PD-L1 Biomarker Testing Market Challenges

2.3.4 PD-L1 Biomarker Testing Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top PD-L1 Biomarker Testing Players by Revenue

3.1.1 Global Top PD-L1 Biomarker Testing Players by Revenue (2021–2026)

3.1.2 Global PD-L1 Biomarker Testing Revenue Market Share by Players (2021–2026)

3.2 Global Top PD-L1 Biomarker Testing Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by PD-L1 Biomarker Testing Revenue

3.4 Global PD-L1 Biomarker Testing Market Concentration Ratio

3.4.1 Global PD-L1 Biomarker Testing Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by PD-L1 Biomarker Testing Revenue in 2025

3.5 Global Key Players of PD-L1 Biomarker Testing Head Offices and Areas Served

3.6 Global Key Players of PD-L1 Biomarker Testing, Products and Applications

3.7 Global Key Players of PD-L1 Biomarker Testing, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 PD-L1 Biomarker Testing Breakdown Data by Type

4.1 Global PD-L1 Biomarker Testing Historic Market Size by Type (2021–2026)

4.2 Global PD-L1 Biomarker Testing Forecasted Market Size by Type (2027–2032)

5 PD-L1 Biomarker Testing Breakdown Data by Application

5.1 Global PD-L1 Biomarker Testing Historic Market Size by Application (2021–2026)

5.2 Global PD-L1 Biomarker Testing Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America PD-L1 Biomarker Testing Market Size (2021–2032)

6.2 North America PD-L1 Biomarker Testing Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America PD-L1 Biomarker Testing Market Size by Country (2021–2026)

6.4 North America PD-L1 Biomarker Testing Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe PD-L1 Biomarker Testing Market Size (2021–2032)

7.2 Europe PD-L1 Biomarker Testing Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe PD-L1 Biomarker Testing Market Size by Country (2021–2026)

7.4 Europe PD-L1 Biomarker Testing Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific PD-L1 Biomarker Testing Market Size (2021–2032)

8.2 Asia-Pacific PD-L1 Biomarker Testing Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2021–2026)

8.4 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America PD-L1 Biomarker Testing Market Size (2021–2032)

9.2 Latin America PD-L1 Biomarker Testing Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America PD-L1 Biomarker Testing Market Size by Country (2021–2026)

9.4 Latin America PD-L1 Biomarker Testing Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa PD-L1 Biomarker Testing Market Size (2021–2032)

10.2 Middle East & Africa PD-L1 Biomarker Testing Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2021–2026)

10.4 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Agilent Technologies

11.1.1 Agilent Technologies Company Details

11.1.2 Agilent Technologies Business Overview

11.1.3 Agilent Technologies PD-L1 Biomarker Testing Introduction

11.1.4 Agilent Technologies Revenue in PD-L1 Biomarker Testing Business (2021–2026)

11.1.5 Agilent Technologies Recent Development

11.2 Roche

11.2.1 Roche Company Details

11.2.2 Roche Business Overview

11.2.3 Roche PD-L1 Biomarker Testing Introduction

11.2.4 Roche Revenue in PD-L1 Biomarker Testing Business (2021–2026)

11.2.5 Roche Recent Development

11.3 Merck

11.3.1 Merck Company Details

11.3.2 Merck Business Overview

11.3.3 Merck PD-L1 Biomarker Testing Introduction

11.3.4 Merck Revenue in PD-L1 Biomarker Testing Business (2021–2026)

11.3.5 Merck Recent Development

11.4 Bristol-Myers Squibb

11.4.1 Bristol-Myers Squibb Company Details

11.4.2 Bristol-Myers Squibb Business Overview

11.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Introduction

11.4.4 Bristol-Myers Squibb Revenue in PD-L1 Biomarker Testing Business (2021–2026)

11.4.5 Bristol-Myers Squibb Recent Development

11.5 AstraZeneca

11.5.1 AstraZeneca Company Details

11.5.2 AstraZeneca Business Overview

11.5.3 AstraZeneca PD-L1 Biomarker Testing Introduction

11.5.4 AstraZeneca Revenue in PD-L1 Biomarker Testing Business (2021–2026)

11.5.5 AstraZeneca Recent Development

11.6 Ono Pharmaceutical

11.6.1 Ono Pharmaceutical Company Details

11.6.2 Ono Pharmaceutical Business Overview

11.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Introduction

11.6.4 Ono Pharmaceutical Revenue in PD-L1 Biomarker Testing Business (2021–2026)

11.6.5 Ono Pharmaceutical Recent Development

11.7 Regeneron

11.7.1 Regeneron Company Details

11.7.2 Regeneron Business Overview

11.7.3 Regeneron PD-L1 Biomarker Testing Introduction

11.7.4 Regeneron Revenue in PD-L1 Biomarker Testing Business (2021–2026)

11.7.5 Regeneron Recent Development

11.8 Innovent

11.8.1 Innovent Company Details

11.8.2 Innovent Business Overview

11.8.3 Innovent PD-L1 Biomarker Testing Introduction

11.8.4 Innovent Revenue in PD-L1 Biomarker Testing Business (2021–2026)

11.8.5 Innovent Recent Development

11.9 Hengrui Medicine

11.9.1 Hengrui Medicine Company Details

11.9.2 Hengrui Medicine Business Overview

11.9.3 Hengrui Medicine PD-L1 Biomarker Testing Introduction

11.9.4 Hengrui Medicine Revenue in PD-L1 Biomarker Testing Business (2021–2026)

11.9.5 Hengrui Medicine Recent Development

11.10 Junshi Biosciences

11.10.1 Junshi Biosciences Company Details

11.10.2 Junshi Biosciences Business Overview

11.10.3 Junshi Biosciences PD-L1 Biomarker Testing Introduction

11.10.4 Junshi Biosciences Revenue in PD-L1 Biomarker Testing Business (2021–2026)

11.10.5 Junshi Biosciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Agilent Technologies

Roche

Merck

Bristol–Myers Squibb

Astrazeneca plc

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

List of Tables

Table 1. Global PD-L1 Biomarker Testing Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of PD-L1 (22C3)

Table 3. Key Players of PD-L1(28-8)

Table 4. Key Players of PD-L1 (SP142)

Table 5. Key Players of PD-L1 (SP263)

Table 6. Key Players of Other

Table 7. Global PD-L1 Biomarker Testing Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 8. Global PD-L1 Biomarker Testing Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 9. Global PD-L1 Biomarker Testing Market Size by Region (US$ Million), 2021–2026

Table 10. Global PD-L1 Biomarker Testing Market Share by Region (2021–2026)

Table 11. Global PD-L1 Biomarker Testing Forecasted Market Size by Region (US$ Million), 2027–2032

Table 12. Global PD-L1 Biomarker Testing Market Share by Region (2027–2032)

Table 13. PD-L1 Biomarker Testing Market Trends

Table 14. PD-L1 Biomarker Testing Market Drivers

Table 15. PD-L1 Biomarker Testing Market Challenges

Table 16. PD-L1 Biomarker Testing Market Restraints

Table 17. Global PD-L1 Biomarker Testing Revenue by Players (US$ Million), 2021–2026

Table 18. Global PD-L1 Biomarker Testing Market Share by Players (2021–2026)

Table 19. Global Top PD-L1 Biomarker Testing Players by Tier (Tier 1, Tier 2, and Tier 3), based on PD-L1 Biomarker Testing Revenue, 2025

Table 20. Ranking of Global Top PD-L1 Biomarker Testing Companies by Revenue (US$ Million) in 2025

Table 21. Global 5 Largest Players Market Share by PD-L1 Biomarker Testing Revenue (CR5 and HHI), 2021–2026

Table 22. Global Key Players of PD-L1 Biomarker Testing, Headquarters and Area Served

Table 23. Global Key Players of PD-L1 Biomarker Testing, Products and Applications

Table 24. Global Key Players of PD-L1 Biomarker Testing, Date of General Availability (GA)

Table 25. Mergers and Acquisitions, Expansion Plans

Table 26. Global PD-L1 Biomarker Testing Market Size by Type (US$ Million), 2021–2026

Table 27. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2021–2026)

Table 28. Global PD-L1 Biomarker Testing Forecasted Market Size by Type (US$ Million), 2027–2032

Table 29. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2027–2032)

Table 30. Global PD-L1 Biomarker Testing Market Size by Application (US$ Million), 2021–2026

Table 31. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2021–2026)

Table 32. Global PD-L1 Biomarker Testing Forecasted Market Size by Application (US$ Million), 2027–2032

Table 33. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2027–2032)

Table 34. North America PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 35. North America PD-L1 Biomarker Testing Market Size by Country (US$ Million), 2021–2026

Table 36. North America PD-L1 Biomarker Testing Market Size by Country (US$ Million), 2027–2032

Table 37. Europe PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 38. Europe PD-L1 Biomarker Testing Market Size by Country (US$ Million), 2021–2026

Table 39. Europe PD-L1 Biomarker Testing Market Size by Country (US$ Million), 2027–2032

Table 40. Asia-Pacific PD-L1 Biomarker Testing Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 41. Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (US$ Million), 2021–2026

Table 42. Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (US$ Million), 2027–2032

Table 43. Latin America PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 44. Latin America PD-L1 Biomarker Testing Market Size by Country (US$ Million), 2021–2026

Table 45. Latin America PD-L1 Biomarker Testing Market Size by Country (US$ Million), 2027–2032

Table 46. Middle East & Africa PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 47. Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (US$ Million), 2021–2026

Table 48. Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (US$ Million), 2027–2032

Table 49. Agilent Technologies Company Details

Table 50. Agilent Technologies Business Overview

Table 51. Agilent Technologies PD-L1 Biomarker Testing Product

Table 52. Agilent Technologies Revenue in PD-L1 Biomarker Testing Business (US$ Million), 2021–2026

Table 53. Agilent Technologies Recent Development

Table 54. Roche Company Details

Table 55. Roche Business Overview

Table 56. Roche PD-L1 Biomarker Testing Product

Table 57. Roche Revenue in PD-L1 Biomarker Testing Business (US$ Million), 2021–2026

Table 58. Roche Recent Development

Table 59. Merck Company Details

Table 60. Merck Business Overview

Table 61. Merck PD-L1 Biomarker Testing Product

Table 62. Merck Revenue in PD-L1 Biomarker Testing Business (US$ Million), 2021–2026

Table 63. Merck Recent Development

Table 64. Bristol-Myers Squibb Company Details

Table 65. Bristol-Myers Squibb Business Overview

Table 66. Bristol-Myers Squibb PD-L1 Biomarker Testing Product

Table 67. Bristol-Myers Squibb Revenue in PD-L1 Biomarker Testing Business (US$ Million), 2021–2026

Table 68. Bristol-Myers Squibb Recent Development

Table 69. AstraZeneca Company Details

Table 70. AstraZeneca Business Overview

Table 71. AstraZeneca PD-L1 Biomarker Testing Product

Table 72. AstraZeneca Revenue in PD-L1 Biomarker Testing Business (US$ Million), 2021–2026

Table 73. AstraZeneca Recent Development

Table 74. Ono Pharmaceutical Company Details

Table 75. Ono Pharmaceutical Business Overview

Table 76. Ono Pharmaceutical PD-L1 Biomarker Testing Product

Table 77. Ono Pharmaceutical Revenue in PD-L1 Biomarker Testing Business (US$ Million), 2021–2026

Table 78. Ono Pharmaceutical Recent Development

Table 79. Regeneron Company Details

Table 80. Regeneron Business Overview

Table 81. Regeneron PD-L1 Biomarker Testing Product

Table 82. Regeneron Revenue in PD-L1 Biomarker Testing Business (US$ Million), 2021–2026

Table 83. Regeneron Recent Development

Table 84. Innovent Company Details

Table 85. Innovent Business Overview

Table 86. Innovent PD-L1 Biomarker Testing Product

Table 87. Innovent Revenue in PD-L1 Biomarker Testing Business (US$ Million), 2021–2026

Table 88. Innovent Recent Development

Table 89. Hengrui Medicine Company Details

Table 90. Hengrui Medicine Business Overview

Table 91. Hengrui Medicine PD-L1 Biomarker Testing Product

Table 92. Hengrui Medicine Revenue in PD-L1 Biomarker Testing Business (US$ Million), 2021–2026

Table 93. Hengrui Medicine Recent Development

Table 94. Junshi Biosciences Company Details

Table 95. Junshi Biosciences Business Overview

Table 96. Junshi Biosciences PD-L1 Biomarker Testing Product

Table 97. Junshi Biosciences Revenue in PD-L1 Biomarker Testing Business (US$ Million), 2021–2026

Table 98. Junshi Biosciences Recent Development

Table 99. Research Programs/Design for This Report

Table 100. Key Data Information from Secondary Sources

Table 101. Key Data Information from Primary Sources

Table 102. Authors List of This Report

List of Figures

Figure 1. PD-L1 Biomarker Testing Picture

Figure 2. Global PD-L1 Biomarker Testing Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global PD-L1 Biomarker Testing Market Share by Type: 2025 vs 2032

Figure 4. PD-L1 (22C3) Features

Figure 5. PD-L1(28-8) Features

Figure 6. PD-L1 (SP142) Features

Figure 7. PD-L1 (SP263) Features

Figure 8. Other Features

Figure 9. Global PD-L1 Biomarker Testing Market Size by Application (US$ Million), 2021–2032

Figure 10. Global PD-L1 Biomarker Testing Market Share by Application: 2025 vs 2032

Figure 11. Hospital Case Studies

Figure 12. Diagnostic Center Case Studies

Figure 13. Others Case Studies

Figure 14. PD-L1 Biomarker Testing Report Years Considered

Figure 15. Global PD-L1 Biomarker Testing Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 16. Global PD-L1 Biomarker Testing Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 17. Global PD-L1 Biomarker Testing Market Share by Region: 2025 vs 2032

Figure 18. Global PD-L1 Biomarker Testing Market Share by Players in 2025

Figure 19. Global PD-L1 Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 20. The Top 10 and 5 Players Market Share by PD-L1 Biomarker Testing Revenue in 2025

Figure 21. North America PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. North America PD-L1 Biomarker Testing Market Share by Country (2021–2032)

Figure 23. United States PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Canada PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. Europe PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. Europe PD-L1 Biomarker Testing Market Share by Country (2021–2032)

Figure 27. Germany PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. France PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. U.K. PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Italy PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Russia PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Ireland PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Asia-Pacific PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Asia-Pacific PD-L1 Biomarker Testing Market Share by Region (2021–2032)

Figure 35. China PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Japan PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. South Korea PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Southeast Asia PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. India PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Australia & New Zealand PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Latin America PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Latin America PD-L1 Biomarker Testing Market Share by Country (2021–2032)

Figure 43. Mexico PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Brazil PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Middle East & Africa PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Middle East & Africa PD-L1 Biomarker Testing Market Share by Country (2021–2032)

Figure 47. Israel PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Saudi Arabia PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. UAE PD-L1 Biomarker Testing Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Agilent Technologies Revenue Growth Rate in PD-L1 Biomarker Testing Business (2021–2026)

Figure 51. Roche Revenue Growth Rate in PD-L1 Biomarker Testing Business (2021–2026)

Figure 52. Merck Revenue Growth Rate in PD-L1 Biomarker Testing Business (2021–2026)

Figure 53. Bristol-Myers Squibb Revenue Growth Rate in PD-L1 Biomarker Testing Business (2021–2026)

Figure 54. AstraZeneca Revenue Growth Rate in PD-L1 Biomarker Testing Business (2021–2026)

Figure 55. Ono Pharmaceutical Revenue Growth Rate in PD-L1 Biomarker Testing Business (2021–2026)

Figure 56. Regeneron Revenue Growth Rate in PD-L1 Biomarker Testing Business (2021–2026)

Figure 57. Innovent Revenue Growth Rate in PD-L1 Biomarker Testing Business (2021–2026)

Figure 58. Hengrui Medicine Revenue Growth Rate in PD-L1 Biomarker Testing Business (2021–2026)

Figure 59. Junshi Biosciences Revenue Growth Rate in PD-L1 Biomarker Testing Business (2021–2026)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

PD L1 and PIK3CA Testing Product Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global PD L1 Biomarker Testing Platform Market Insights Forecast to 2030

Global PD 1 PD L1 Checkpoint Inhibitors Market Research Report 2024

Global PDL1 Antibody Reagent Immunohistochemistry Market Research Report 2024

IHC Detection Kits Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global PD 1 and PDL 1 Inhibitors Market Research Report 2025

Pd 1 and Pd L1 Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Immunohistochemistry Transmitter Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Checkpoint Inhibitors for Treating Cancer Market Insights Forecast to 2030

Immunohistochemistry IHC Antigen Retrieval Solution Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Immuno Oncology Assays Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

PD 1 and PD L1 Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Immune Checkpoint Inhibitors for Cancer Market Research Report 2024

Global Immuno Oncology Assays Kit Market Insights Forecast to 2030

Global Combination Antibody Therapy Market Research Report 2024

Global PD 1 and PD L1 Monoclonal Antibody Market Research Report 2025

Global Automated IHC Staining System Market Research Report 2024

Global Immunoglobulin G Antibody Therapeutics Market Insights Forecast to 2030

Global Immunohistochemistry IHC Testing Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions